FINWIRES · TerminalLIVE
FINWIRES

$NTLA

2 stories mentioning NTLAUpdated 1d ago

Every FINWIRES story that references NTLA, newest first.

Wire

Wedbush Adjusts Intellia Therapeutics Price Target to $12 From $17, Maintains Neutral Rating

Wedbush Adjusts Intellia Therapeutics Price Target to $12 From $17, Maintains Neutral Rating

$NTLA
Wire

Wedbush Raises Intellia Therapeutics Price Target to $17 From $12, Maintains Neutral Rating

Wedbush Raises Intellia Therapeutics Price Target to $17 From $12, Maintains Neutral Rating

$NTLA

Track with the FINWIRES app suite

FolioX
FolioX
Track NTLA in your portfolio
WheelAI
WheelAI
Analyze NTLA options with the wheel strategy
StockInsider
StockInsider
See market sentiment on NTLA